The Week

Alpha Tau Medical (DRTS) rose 5.61% this week to close at $15.24, outperforming the S&P 500, which slipped 0.08%, by roughly 5.69 percentage points. The week played out as a rally followed by a modest pullback: the stock opened at $14.11 on Monday, climbed steadily through Thursday when it hit the week’s high of $15.79, then gave back some gains to end at $15.24 on Friday. Weekly amplitude came to 11.91%. Activity was slightly elevated, with average daily volume of 591,000 shares running about 3.21% above the past 60 days’ median.

Key Events

This week’s news flow revolved around the company’s early cancer trial readouts. A Tuesday report noted that Alpha Tau’s cancer trials keep beating expectations, with three major data readouts coming next. Thursday’s coverage centred on the strong early cancer trial signals the company posted and key readouts ahead. By Friday, attention shifted to how early trial results will impact the stock. None of the three items offered specific trial details, but the thread was consistent: markets are waiting for critical clinical data from Alpha Tau’s alpha-particle therapy, and the stock touched its weekly high on Thursday against that backdrop.

Analyst Ratings

Five institutions cover the stock, with three buy and one overweight ratings, one hold, and no underweight or sell ratings. The consensus rating is buy, with a consensus target price of $17.80, about 16.80% above the latest close of $15.24. Target prices range from $8.00 to $30.00, pointing to wide dispersion across the street. Within medical devices, the stock ranks 60th out of 142 names covered in the sector.

The Week Ahead

The macro calendar is fairly heavy next week. The US Richmond Fed composite index lands on Tuesday, with a prior reading of 4. Wednesday brings EIA weekly crude oil and Cushing crude oil inventories. Thursday is the busiest, with initial jobless claims, the current account balance, new home sales and EIA natural gas storage all on deck. Alpha Tau itself has not announced a new earnings or clinical data date, but the timing of those three cancer trial readouts remains the central company-specific variable to watch.

In Short

Alpha Tau Medical’s price action and news flow this week ran along the same line: key early cancer trial data are due soon, and the stock advanced on that anticipation while outpacing the broader market. On the analyst side, most brokers rate the shares buy, with the consensus target sitting above spot, although the wide target range between $8.00 and $30.00 shows sharp disagreement. The latest session’s fund flows were mixed: large-lot money turned net seller while medium and small orders were net buyers. What to watch next is whether clinical data meet expectations and whether the stocks relative strength can persist.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.